Industry-Funded CME To Go Way Of Dinosaurs? ACCME Comments Lumber In
Executive Summary
The pharmaceutical industry continues to retrench how it provides continuing medical education in response to public and congressional pressure, but firms are also marshalling for a fight against an outright ban
You may also be interested in...
Social Networking Sites: Small Step For Firms, Giant Leap For Research
As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets
Social Networking Sites: Small Step For Firms, Giant Leap For Research
As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets
CME providers to pay more to be monitored
To finance tighter oversight of continuing medical education programs, the Accreditation Council for Continuing Medical Education is phasing in higher accreditation fees over the next three years. Initial increases will occur in 2009, including a special assessment that could be as high as $7,000, depending on an accredited provider's reported expenses. CME is a major component in the debate about industry influence on physicians' prescribing patterns, prompting Pfizer to curtail its support for CME and ACCME to propose limits on industry funding (1"The Pink Sheet," Sept. 29, 2008, p. 18)